Showing results (31-40 of 102) with videos related to

Sort By:
Pageof 11
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexedMugdha Patki, Shirish Gadgeel, Yanfang Huang, et al.
Clinical Lung Cancer|March 10, 2025
Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung CancersRadhika Gutta, Emily Teslow, Ellen Jaeger, et al.
Lung Cancer (Auckland, N.Z.)|October 2, 2019
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitorsMisako Nagasaka, Nadine Abdallah, Marcus Crosby, et al.
Clinical Lung Cancer|November 17, 2023
A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerAngel Qin, Leah Wells, Binu Malhotra, et al.
The Journal of Biological Chemistry|January 1, 2022
Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticityJitender Monga, Indra Adrianto, Craig Rogers, et al.
Lung Cancer (Amsterdam, Netherlands)|November 10, 2006
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapyGregory J Riely, Shirish Gadgeel, Ivan Rothman, et al.
Advances in Radiation Oncology|May 8, 2023
Clinical Outcome in Patients With Early-Stage Small Cell Lung Cancer Treated With Surgery or Radiation in the Absence of Prophylactic Cranial Irradiation: A Single-Center Retrospective StudySondos Al Khatib, Khalid Adil, Lonni Schultz, et al.
Clinical Lung Cancer|June 15, 2007
Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancerAntoinette J Wozniak, Kimberly Belzer, Lance K Heilbrun, et al.
Clinical Epidemiology|November 9, 2016
Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survivalJennifer L Beebe-Dimmer, Jon P Fryzek, Cecilia L Yee, et al.
Investigational New Drugs|November 15, 2006
A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitorAmin M Alousi, Ramesh Boinpally, Richard Wiegand, et al.
Pageof 11